# Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote

> **NCT03218241** · PHASE1 · COMPLETED · sponsor: **Portola Pharmaceuticals** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** PRT064445
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03218241
- **Lead sponsor:** Portola Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2012-09
- **Final completion:** 2012-10
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03218241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03218241, "Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03218241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*